Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New registry aims to personalize blood thinners after TAVR

NCT ID NCT06000943

Knowledge-focused Sponsor: Niguarda Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study follows 2500 people who had a TAVR procedure to replace a narrowed heart valve. Researchers will track bleeding and clotting events over time to see how different blood-thinner medicines affect risk. The goal is to find the best treatment plan for each patient based on their surgical risk level.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors choose the safest blood-thinner plan for each patient after TAVR, reducing heart attacks, strokes, and bleeding.
What could go wrong
This is an observational registry, not a treatment test. It can show patterns but cannot prove which therapy is best. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 2,500 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2023

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Consecutive patients with severe aortic stenosis diagnosed according to ESC guidelines, undergoing TAVR

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria * All patients with severe aortic stenosis undergoing TAVR. * Availability of changes in antithrombotic therapy at 1 month, 90 days, and 1 year after TAVR. Exclusion Criteria * Patients who died during the index procedure * Patients in triple antithrombotic therapy at discharge * Patients with a known prognosis less than 1 year at the time of TAVR

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Aortic valve stenosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

aortic valve stenosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Aortic valve stenosis Transcatheter aortic valve replacement

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    12 sites in 5 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • A.O.U. Città della Salute e della Scienza di Torino

    RECRUITING

    Torino, Italy

  • ASST GOM Niguarda

    RECRUITING

    Milan, Italia, 20162, Italy

  • Azienda Ospedaliera Sant'Andrea

    RECRUITING

    Roma, Italy

  • Cardiocenter, 3rd Medical School, Charles University and University Hospital Kralovske Vinohrady

    RECRUITING

    Prague, 10034, Czechia

  • Complejo Asistencial Dr. Sótero del Río

    RECRUITING

    Santiago, Chile

  • Humanitas Research Hospital

    RECRUITING

    Rozzano, Milano, 20089, Italy

  • IRCCS Ospedale Policlinico San Martino

    RECRUITING

    Genova, Italy

  • IRCCS Policlinico San Donato

    RECRUITING

    San Donato Milanese, Milano, Italy

  • OLV Hospital

    RECRUITING

    Aalst, Belgium

  • Ospedale Galeazzi Sant'Ambrogio

    RECRUITING

    Milan, Italy

  • Puerto Real University Hospital, Puerto Real

    RECRUITING

    Cadiz, Spain

  • San Carlo Hospital

    RECRUITING

    Potenza, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.